Managing and Maintaining Clinical Response in Moderately to Severely Active Crohn’s Disease: Efficacy and Safety of CIMZIA^® (Certolizumab Pegol)

The increase in treatment options has been an important advance for the goal of achieving a sustained remission in patients with moderate-to-severe Crohn’s disease (CD). It is important to recognize that biologic agents, including those within the TNF drug class, are not interchangeable. CIMZIA^® (certolizumab pegol), either the first- or second-line setting, is distinguished by its unique formulation, pegylation, and other features, including self-injection, that make it a possible choice in selected patients. Ultimately, shared decision-making involves multiple factors, including patient preferences and cost. The goal for use of CIMZIA and other TNFi agents or other biologics is selecting an agent which the patient can adhere to long term. This should be a goal of therapy for the individualization of therapy in moderate-to-severe CD.